BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 24762071)

  • 21. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
    J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.
    Garnock-Jones KP
    Drugs; 2014 Mar; 74(4):489-504. PubMed ID: 24604792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging injectable therapies for multiple sclerosis.
    Oh J; Calabresi PA
    Lancet Neurol; 2013 Nov; 12(11):1115-26. PubMed ID: 24090587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab therapy for multiple sclerosis.
    Coles AJ
    Neurotherapeutics; 2013 Jan; 10(1):29-33. PubMed ID: 23184314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
    ; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
    N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug safety evaluation of alemtuzumab for multiple sclerosis.
    Willis M; Robertson NP
    Expert Opin Drug Saf; 2014 Aug; 13(8):1115-24. PubMed ID: 24935240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
    Klotz L; Meuth SG; Wiendl H
    Clin Immunol; 2012 Jan; 142(1):25-30. PubMed ID: 21550857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
    Jones JL; Anderson JM; Phuah CL; Fox EJ; Selmaj K; Margolin D; Lake SL; Palmer J; Thompson SJ; Wilkins A; Webber DJ; Compston DA; Coles AJ
    Brain; 2010 Aug; 133(Pt 8):2232-47. PubMed ID: 20659956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab: the advantages and challenges of a novel therapy in MS.
    Menge T; Stüve O; Kieseier BC; Hartung HP
    Neurology; 2014 Jul; 83(1):87-97. PubMed ID: 24920854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
    Fox EJ; Sullivan HC; Gazda SK; Mayer L; O'Donnell L; Melia K; Lake SL
    Eur J Neurol; 2012 Feb; 19(2):307-11. PubMed ID: 21899662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [ALEMTUZUMAB: BENEFITS AND CHALLENGES OF A NEW THERAPY IN MULTIPLE SCLEROSIS].
    Illés Z; Sejbaek T; Csépány T
    Ideggyogy Sz; 2015 May; 68(5-6):155-64. PubMed ID: 26182606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.